Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2015. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of June 30, 2015:
- Total Issued Ordinary Shares: 5,357,905,535 (25p each)
- Treasury Shares: 491,515,950
- Total Voting Rights: 4,866,389,585
No material changes to financial performance or operational status are reported in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,866,389,585) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (491,515,950) to calculate the correct denominator for ownership percentage calculations.
- Review the Company's Form 20-F for comprehensive financial performance data, as this Form 6-K contains no financial metrics.